Have questions? reach out
WBL Exclusive Genomic & Epigenomic Solutions
Direct Whole Methylome Sequencing (gDNA)Direct Methylation Sequencing (cfDNA)Direct Targeted Methylation Sequencing (gDNA)
Have questions? reach out
Wasatch BioLabs, a leading NGS sequencing service provider, harnesses advanced native-read sequencing and streamlined R&D workflows, translating breakthrough discovery into real-world outcomes.
High-throughput solutions powering academic and translational studies.
[1]
End-to-end tools for advanced biomarker discovery and development.
[2]
Scalable sequencing built for precision diagnostics and real-world deployment.
[3]
Legacy methods like microarrays and bisulfite sequencing lack the resolution and scalability needed for clinical impact, limiting biomarker discovery and slowing adoption in precision health. Wasatch BioLabs’ Direct Whole Methylome (dWMS) platform is a nanopore-based solution optimized through proprietary library preparation and dWMS-specific bioinformatics. By building on the core strengths of Oxford Nanopore Technologies, dWMS delivers high-resolution, end-to-end methylation and variant analysis designed for real-world research and clinical use.
[01]
Directly detect native methylation—no bisulfite or PCR required.
[02]
Increase throughput and read quality, with proprietary protocols.
[03]
Profile methylation and structural variants from a single unified assay.
[04]
Built for multiplexing, cohort studies, and diagnostic-ready workflows.
[05]
Leverage our MethylSeqR tools and expert team for end-to-end support.
[06]
Tailor coverage depth and protocols to meet your research objectives.
[Our advantages]
Built on Oxford Nanopore technology, Wasatch BioLabs’ targeted platform eliminates amplification and bisulfite conversion, enabling streamlined, dual-mode profiling of genomic and epigenomic data. With flexible Agilent SureSelect and Avida probe-based panel design, researchers can target up to ~50 genes, promoter regions, or methylation hot spots with 50–150x coverage.
Our platform delivers the depth and precision to confidently detect germline and somatic variants, rare frequency alleles, and methylation changes—providing comprehensive coverage across even the most biologically complex regions.
Comprehensive Depth
The native sequencing approach captures full-length, unmodified DNA molecules—enabling simultaneous detection of CpG, CHG, and CHH methylation, structural variants, and phasing of germline and somatic mutations without the bias introduced by PCR or bisulfite conversion.
Native-Sequencing
Built for high-throughput applications, our platform supports flexible multiplexing and streamlined workflows, making it a cost-effective solution for large cohort studies, population-scale research, and clinical assay deployment.
Scalability
Leveraging Agilent probes, the dTMS platform sequences only what matters, supporting custom panels, multiplexing, and high-throughput analyses for population studies, translational research, and clinical assay development.
Long-read nanopore sequencing resolves complex regions with high accuracy, detecting CNVs, structural variants, phasing, and base modifications in a single assay for targeted panels and large-scale studies.
Direct, native DNA sequencing captures CpG, CHG, and CHH methylation alongside structural and germline variants. Preserving true methylation states without PCR or bisulfite bias, dTMS enables comprehensive, base-level insight into epigenetic and genomic architecture.
[Our advantages]
.gif)
Wasatch BioLabs is the first full-scale clinical lab dedicated to Oxford Nanopore sequencing, offering proprietary platforms like dWMS and standard ONT services for flexible research support.
Wasatch BioLabs empowers research and clinical innovation through advanced native-read sequencing solutions. Our high-throughput technology systems support academic studies, biomarker discovery, and real-world clinical deployment, translating breakthrough discovery into tangible outcomes.
Yes. Wasatch BioLabs provides scalable sequencing solutions built for precision clinical testing. Our services are designed for real-world clinical use, with systems like dWMS tailored for clinical-ready workflows and cohort studies.
Yes — we are certified to CLIA and we are CLEP-ready and FDA-ready. Our experienced team can help guide clients from early discovery work, through clinical validation, and into patient testing phases.
As your clinical lab partner, we have expertise and are willing to expand our regulatory scope such as with medical devices, companion diagnostics, and IVDs (ISO 13485), international clinical labs (ISO 15189), MDSAP, ISO 14197, IVDR, M.O. 169, etc.
Available sequencing services include Direct Whole Methylome Sequencing (dWMS), Direct Targeted Methylation Sequencing, biomarker discovery, custom assay development, and standard Oxford Nanopore Technologies (ONT) services—supporting both genomic, epigenomic, and transcriptomic profiling.
To get started, visit the Wasatch BioLabs website and explore their service offerings. You can also reach out via their Contact page or subscribe for updates. They provide custom support across research and clinical applications.
